Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

ASTX727/Venetoclax Combo Is Safe and Effective in First-Line and Relapsed/Refractory AML

October 5th 2022

Oral decitabine plus cedazuridine added to oral venetoclax demonstrated promising overall response rates in patients with acute myeloid leukemia who received the combination as a first-line treatment or after relapsing on prior therapies.

Zanubrutinib Provides ORR, PFS Benefits Over Ibrutinib in Relapsed/Refractory CLL/SLL

October 4th 2022

Zanubrutinib elicited significantly higher response rates and survival benefits compared with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma .

Loncastuximab Tesirine/Rituximab Elicits Promising Anti-Tumor Activity in Relapsed/Refractory DLBCL

October 3rd 2022

Loncastuximab tesirine-lpyl combined with rituximab demonstrated encouraging antitumor activity and a feasible safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma.

Momelotinib Improves OS in Patients With Myelofibrosis and Low Platelet Counts

October 3rd 2022

Momelotinib induced superior 24-week overall survival rates compared with danazol in thrombocytopenic, symptomatic, and anemic patients with myelofibrosis.

Ivosidenib/Azacitidine Combo Elicits Survival Benefit Over Placebo in IDH1-Mutated AML

September 29th 2022

Ivosidenib plus azacitidine displayed favorable event-free survival, overall survival, and clinical responses compared with placebo plus azacitidine in patients with newly diagnosed, IDH1-mutated acute myeloid leukemia, according to findings from the phase 3 AGILE study.

Japan Green Lights Valemetostat Tosilate for Relapsed/Refractory Adult T-cell Leukemia/Lymphoma

September 26th 2022

The Japan Ministry of Health, Labor and Welfare has approved valemetostat tosilate for the treatment of patients with relapsed or refractory adult T-cell leukemia/lymphoma.

Duvelisib Loses Support for CLL/SLL Indication Following ODAC Meeting

September 23rd 2022

In an 8 to 4 vote, the FDA’s Oncologic Drugs Advisory Committee voted that the final overall survival data submitted did not demonstrate a strong enough benefit-risk ratio for duvelisib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after at least 2 prior therapies.

Zanubrutinib Approaches European Approval for Marginal Zone Lymphoma

September 19th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of zanubrutinib for use in adult patients with marginal zone lymphoma who have received at least 1 prior anti–CD20-based therapy.

Axi-cel Receives Positive Opinion from EU for DLBCL/HGBL

September 19th 2022

The European Medicines Agency Committee for Medicinal Products for Human Use has granted a positive opinion for axicabtagene ciloleucel for the treatment of adult patients with diffuse large B-cell lymphoma and high-grade B-cell lymphoma who relapse within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Dr. Goy on Updates in Precision Medicine in Hematologic Malignancies

September 15th 2022

Andre H. Goy, MD, discusses updates in precision medicine.

Dr. McCloskey on the Efficacy of CPX-351 in FLT3-Mutated AML

September 15th 2022

James K. McCloskey, MD, discusses the efficacy of CPX-351 in FLT3-mutated acute myeloid leukemia.

Fellows’ Passion Keeps Deol Sharp and Up to Date

September 14th 2022

Abhinav Deol, MD, discusses how Karmanos Cancer Institute prepares trainees for their first job and helps them handle negative situations and deal with grief.

Dr. Verstovsek on Pemigatinib in FGFR1-Rearranged Myeloid Neoplasms

September 14th 2022

Srdan Verstovsek, MD, PhD, discusses the FDA approval of pemigatinib, an FGFR1 inhibitor, in patients with myeloid neoplasms with an FGFR1 rearrangement.

Pemigatinib Represents Transformative Treatment for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

September 13th 2022

Srdan Verstovsek, MD, PhD, discusses the clinical implications of the FDA approval of pemigatinib, the results of the FIGHT-203 trial, and the need to conduct chromosomal analysis for patients with myeloid/lymphoid neoplasms.

ctDNA Could Serve as a Prognostic Tool in China for Predicting Outcomes in DLBCL

September 12th 2022

Results from a retrospective analysis presented during the 2022 ESMO Congress indicated that circulating tumor DNA could potentially be leveraged as a prognostic factor and a tumor-specific biomarker for diffuse large B-cell lymphoma in China.

Orelabrutinib Plus R-CHOP Demonstrates Impressive ORR, PFS Rates in Non-GCB DLBCL

September 12th 2022

The combination of orelabrutinib and R-CHOP elicited a favorable overall response rate and progression-free response rate in patients with previously untreated non–germinal center B-cell–like diffuse large B-cell lymphoma (DLBCL) with extranodal disease.

Hodgkin Lymphoma Pioneer Saul A. Rosenberg, MD, FASCO, Dies at 95

September 8th 2022

Saul A. Rosenberg, MD, FASCO, the Maureen Lyles D’Ambrogio Professor Emeritus at Stanford School of Medicine and the 2019 Giants of Cancer Care® award winner for Lymphoma, died at the age of 95.

Azacitidine/Venetoclax Combo Delivers Promising Early Results in High-Risk CML, MDS

September 8th 2022

Azacitidine plus venetoclax showed encouraging activity in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.

Chen Discusses Diagnosis, Management, and Disparities in Cutaneous T-cell Lymphoma

September 8th 2022

Dr Chen details the findings from a study of patients with transformed cutaneous T-cell lymphoma, gives her perspective on findings from the FLASH trial, and discusses the need for more research funding in this disease.

European Commission Grants Orphan Drug Designation to Nana-val for Peripheral T-cell Lymphoma

September 8th 2022

The European Commission has granted an orphan drug designation to nanatinostat and valganciclovir for use as a potential therapeutic option in patients with peripheral T-cell lymphoma.